Literature DB >> 2209702

The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.

M Eto1, H Mayumi, Y Tomita, Y Yoshikai, Y Nishimura, K Nomoto.   

Abstract

Mechanisms of cyclophosphamide (CY)-induced tolerance were studied. When C3H/He Slc (C3H; H-2k, Mls-1b) mice were primed i.v. with 1 x 10(8) viable spleen cells from H-2-identical AKR/J Sea (AKR; H-2k, Mls-1a) mice and treated with 200 mg/kg of CY 2 days later, a long-lasting skin allograft tolerance to AKR was established. When [C57BL/6 Sea (B6; H-2b, Mls-1b) x AKR]F1 (B6AKF1) cells were used as the tolerogen, however, only a moderate, but not long-lasting, skin tolerance to AKR was observed. In the C3H mice treated with AKR cells and CY, the intrathymic clonal deletion of V beta 6+ T cells, which are strongly correlated with reactivity to Mls-1a antigens, was observed in the chimeric thymus on day 35, although neither the clonal deletion of V beta 6-bearing T cells nor the mixed chimerism was observed in the thymus on day 14. In the C3H mice treated with B6AFKF1 cells followed by CY, however, neither the clonal deletion of V beta 6+ T cells nor the mixed chimerism was observed in the thymus throughout the test period. In the lymph nodes of the C3H mice treated with AKR cells and CY, only CD4+ V beta 6+ T cells, bur not CD8+V beta 6+ T cells, had selectively decreased by day 14, and they were hardly detectable on day 35. The selective decrease of CD4+V beta 6+ T cells in the lymph nodes was also observed by day 14 when B6AKF1 cells were used as the tolerogen, although CD4+V beta 6+ T cells gradually increased on day 35, at which time almost all skin grafts from AKR had already been rejected. These results strongly support the necessity of the intrathymic mixed chimerism and clonal deletion of donor-reactive T cells for a long-lasting skin allograft tolerance in CY-induced tolerance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209702     DOI: 10.1002/eji.1830200919

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice.

Authors:  M Eto; Y Y Kong; J Uozumi; S Naito; K Nomoto
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

Review 2.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Authors:  Ashley T Munchel; Yvette L Kasamon; Ephraim J Fuchs
Journal:  Best Pract Res Clin Haematol       Date:  2011-07-13       Impact factor: 3.020

4.  Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.

Authors:  M Eto; Y Yoshikai; Y Nishimura; K Hiromatsu; T Maeda; K Nomoto; Y Y Kong; R T Kubo; J Kumazawa; K Nomoto
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

5.  Efficacy and limitations of natural killer cell depletion in cyclophosphamide-induced tolerance.

Authors:  Ichiro Shimizu; Yukihiro Tomita; Shinji Okano; Toshiro Iwai; Takashi Kajiwara; Tatsushi Onzuka; Ryuji Tominaga
Journal:  Surg Today       Date:  2007-01-01       Impact factor: 2.549

6.  Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Authors:  Sudipto Ganguly; Duncan B Ross; Angela Panoskaltsis-Mortari; Christopher G Kanakry; Bruce R Blazar; Robert B Levy; Leo Luznik
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

7.  Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.

Authors:  Hirohisa Nakamae
Journal:  Int J Hematol       Date:  2022-08-05       Impact factor: 2.319

8.  Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming.

Authors:  T Maeda; M Eto; Y Nishimura; K Nomoto; Y Y Kong; K Nomoto
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

9.  Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.

Authors:  Lucas P Wachsmuth; Michael T Patterson; Michael A Eckhaus; David J Venzon; Ronald E Gress; Christopher G Kanakry
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 19.456

Review 10.  Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.

Authors:  Natalia S Nunes; Christopher G Kanakry
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.